D/C Bio

Bio-Investor, Taiwan Based. Opinions are my own.

[Matt Ridley @mattwridley]

Corruption does not come much more blatant than petitioning somebody to whom you supply BILLIONS of dollars in funding to nominate you for a lucrative prize.

"Dear friend, here's a huge grant; please nominate me for a rich prize."

[D/C Bio @Dustin_tw]

Annji stands among the very few biotech companies in Taiwan with genuinely cutting-edge expertise in translational and clinical development. I earnestly hope Rosolutamide (AJ201) will ultimately deliver meaningful benefit to SBMA patients in need. https://t.co/0DEYN3hw0f

[D/C Bio @Dustin_tw]

THE BEST IS YET TO COME. $7754.TT

[共同通信PRワイヤー @kyodonewsprwire]

FDA Grants Fast Track Designation for AJ201, a First-in-Class Therapy for Kenndy's Disease【AnnJi Pharmaceutical Co., Ltd.】
https://t.co/35mWJi49rU

[D/C Bio @Dustin_tw]

Congratulations to AnnJi Pharma (TWO:7754) on having its Phase 1/2 clinical trial results of lead asset AJ201 on Kennedy Disease recognized with LATE-BREAKING ORAL PRESENTATION in #WMS2025. The presentation will be delivered by Dr. Christopher Grunseich, the head of NIND, NIH.

[D/C Bio @Dustin_tw]

Phase 2a clinical trial results of SBMA (Kennedy disease) from Annji Pharm AJ201 was selected as late-breaking oral presentation of World Muscle Congress 2025 WMS2025 https://t.co/rKJZsdJwiZ

[D/C Bio @Dustin_tw]

Wish collaborative efforts from Annji, medical research community, and advocacy friends bring hope to Kennedy Disease patients in the near future. https://t.co/1aMu4ckGY1 @UkKennedys @disease_kennedy

[D/C Bio @Dustin_tw]

@BertrandBio $2616.HK Data seems decent https://t.co/1O0oXwmxkd

[D/C Bio @Dustin_tw]

Taiwan’s First Ever Baseball World Champion

[WBSC ⚾🥎 @WBSC]

🏆 Congratulations Chinese Taipei the Premier12 2024 presented by RAXUS Champions!

#Premier12

[Kevin McCarthy @SpeakerMcCarthy]

The friendship between America and the people of Taiwan has never been stronger. It is my honor to welcome President @iingwen to the @Reagan_Library.

[D/C Bio @Dustin_tw]

@DrRiyazShah @BTOGORG Agreed... though their trial is designed for the 1st line setting (trial started since 2016)

[D/C Bio @Dustin_tw]

@DrRiyazShah @BTOGORG Baseline: pathology type - 48% biphasic, 52% sarcomatoid

[D/C Bio @Dustin_tw]

@DrRiyazShah @BTOGORG OS K-M plot

[D/C Bio @Dustin_tw]

@DrRiyazShah @BTOGORG FYI. slides are only available in Mandarine

[D/C Bio @Dustin_tw]

@DrRiyazShah @RenoHemonc @BTOGORG It seems that they removed ASS expression from inclusion

[D/C Bio @Dustin_tw]

Very detail discussion and case study of scientific reasoning from EVP of NCKU Dr. MD. Lai (in Mandarine), def worth your time: critical reading of biomedical research papers https://t.co/T1D1vCvxhM

[D/C Bio @Dustin_tw]

No expert for med chem. Good guess for Insilco’s first asset https://t.co/sKVpJJtzNy

[Insilico Medicine @InSilicoMeds]

Starting the week off the most amazing news. Excited to announce our collaboration with Arvinas - the original inventors of protein degradation technology - PROTAC #collaboration #biotech #biotechnology #drugdiscovery https://t.co/FsRY588D9Z

[Insilico Medicine @InSilicoMeds]

Following a major AI breakthrough that we announced earlier in Feb 2021, Insilico Medicine is excited to share today we’ve closed $255M in Series C led by Warburg Pincus w/ participation from a venerable group of investors:

https://t.co/Sh106MTkWN

[C. Michael Gibson MD @CMichaelGibson]

How can there be disagreement between groups about the effectiveness of a drug in an interim analysis? I have NO specific information about the AZ analysis, but let me make some GENERAL comments (thread)